DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 197 filers reported holding DENALI THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.23 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $4,502 | -30.5% | 218,194 | -0.6% | 0.05% | -27.0% |
Q2 2023 | $6,476 | +26.9% | 219,448 | -0.9% | 0.06% | +23.5% |
Q1 2023 | $5,103 | -11.1% | 221,500 | +7.3% | 0.05% | -15.0% |
Q4 2022 | $5,742 | -99.9% | 206,500 | +16.5% | 0.06% | -6.2% |
Q3 2022 | $5,438,000 | -1.4% | 177,196 | +3.3% | 0.06% | +18.5% |
Q1 2022 | $5,517,000 | -27.9% | 171,496 | 0.0% | 0.05% | -20.6% |
Q4 2021 | $7,648,000 | -11.6% | 171,496 | 0.0% | 0.07% | -16.0% |
Q3 2021 | $8,652,000 | -36.9% | 171,496 | -1.9% | 0.08% | -35.7% |
Q2 2021 | $13,711,000 | +73.6% | 174,796 | +26.4% | 0.13% | +61.5% |
Q1 2021 | $7,897,000 | -28.1% | 138,296 | +5.4% | 0.08% | -29.1% |
Q4 2020 | $10,989,000 | +133.8% | 131,196 | 0.0% | 0.11% | +107.5% |
Q3 2020 | $4,701,000 | +48.2% | 131,196 | 0.0% | 0.05% | +39.5% |
Q2 2020 | $3,172,000 | +38.1% | 131,196 | 0.0% | 0.04% | +18.8% |
Q1 2020 | $2,297,000 | – | 131,196 | – | 0.03% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Crestline Management, LP | 19,462,500 | $298,165,000 | 48.02% |
Bratton Capital Management, L.P. | 953,035 | $14,600,000 | 28.53% |
Flagship Pioneering Inc. | 8,005,747 | $122,648,000 | 6.71% |
Casdin Capital, LLC | 650,000 | $9,958,000,000 | 1.03% |
Temasek Holdings (Private) Ltd | 4,410,457 | $67,568,000 | 0.50% |
MARK ASSET MANAGEMENT LP | 68,864 | $1,055,000 | 0.26% |
IRONWOOD INVESTMENT MANAGEMENT LLC | 22,507 | $345,000 | 0.26% |
Artal Group S.A. | 400,000 | $6,128,000 | 0.25% |
PIER 88 INVESTMENT PARTNERS LLC | 40,610 | $622,000 | 0.24% |
HAMILTON LANE ADVISORS LLC | 30,948 | $474,000 | 0.20% |